The effects of @entity2857 for Chinese @entity1 with metastatic @entity1358 (mRCC) were evaluated to figure out the relationship between clinical variables and prognosis. The data were analyzed retrospectively from six comprehensive @entity5 centers in Northeast China. All cases were diagnosed as mRCC histopathologically without exception. @entity1 were taken 400 mg @entity2857 orally twice daily until progression of disease or intolerable toxic reaction occurred. @entity1349 ( @entity1349 ), progression-free survival (PFS), and the influence of clinical variables on survival were appointed as main outcome measures. Clinical data were analyzed using SPSS statistical software. P<0.05 was considered as statistically significant. A total of 131 @entity1 were available for survival analysis. The median follow-up periods were 16.9 months, and the median @entity1349 and PFS were 16.1 months and 10.5 months, respectively. Univariate analysis showed that Eastern Cooperative Oncology Group performance status (ECOG PS), metastatic sites, and previous therapy were significantly associated with @entity1349 , whereas PFS was merely associated with ECOG PS and previous therapy. The multivariate analysis suggested that ECOG PS, metastatic sites, and previous therapy were the independent prognostic factors for @entity1349 , and ECOG PS and previous therapy as the independent prognostic factors for PFS. In the subgroup analysis for @entity1 with visceral @entity3 , the prognosis of @entity1 with lung @entity3 alone was better than those cases with liver @entity3 alone or multiple organs @entity3 . In our study, @entity2857 shows a higher curative activity for @entity1 with mRCC in Northeast China. ECOG PS, metastatic lesions, and previous therapy may be important parameters for @entity1349 and PFS prediction. Lung metastases alone may be a more sensitive indicator for @entity2857 than other organ metastases.

Prognostic analysis of Chinese @entity1 with @entity3 @entity1358 receiving XXXX : results from a multicenter long-term follow-up retrospective study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity2857 :: (MESH:C471405,Chemical) :: ['sorafenib']
